logo
  

Alnylam : Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy Meets Main Goal

Alnylam Pharmaceuticals Inc. (ALNY) said that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated or ATTR amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo.

The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo, as measured by the Kansas City Cardiomyopathy Questionnaire.

Patisiran also demonstrated an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran arm.

The company looks forward to sharing full results at an upcoming conference in September, and it plans to submit a supplemental NDA for patisiran with the U.S. Food and Drug Administration in late 2022.

Transthyretin-mediated amyloidosis is a rare, rapidly progressive, debilitating disease caused by misfolded transthyretin (TTR) proteins which accumulate as amyloid fibrils in multiple tissues including the nerves, heart, and gastrointestinal (GI) tract.

There are two different types of ATTR amyloidosis - Hereditary ATTR (hATTR) amyloidosis, caused by a TTR gene variant, and Wild-type ATTR amyloidosis, which occurs without a TTR gene variant.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla CEO Elon Musk announced that the luxury electric vehicle maker has started the production of Tesla Semi electric trucks, and the first delivery will be to food and beverages giant Pepsico Inc. starting December 1. In a tweet, Musk said, "Excited to announce start of production of Tesla Semi Truck with deliveries to @Pepsi on Dec 1st!" Ford Motor is increasing the entry-level price of its electric F-150 Lightning pickup citing rising costs and supply chain issues amid increasing demand. This is the second price hike after a recent increase in August. The starting price of the 2023 model year pickup will be raised by $5,000 by October 24, reports said citing an email statement. Constellation Brands, Inc. (STZ) said it delivered another quarter of strong business performance. Beer Business achieved double-digit net sales growth for the quarter, while Wine and Spirits net sales rose 1%. The solid top-line performance of its Beer and Wine and Spirits Businesses in the first half...
Follow RTT